Lilly publishes latest corporate responsibility report

Lilly has published its corporate responsibility report for the 2012-13 period, during which it made progress on a number of its social enrichment goals and efforts.

During the period, the company provided $30 million (18.41 million pounds) to fight the burden of non-communicable diseases in developing nations, while pledging an additional $30 million to fund a new scheme to support healthcare provider training and access to medicines.

Additionally, since 2011 nearly 600 employees have devoted around 24,000 hours to the Connecting Hearts Abroad volunteer programme, while more than 360 new clinical trial sites have been added with minority patient populations of more than 25 percent.

The company has also been able to decrease its corporate water intake and greenhouse gas emissions, and made progress on improving its workplace diversity.

Dr John Lechleiter, Lilly's chairman, president and chief executive officer, said: "Lilly's greatest contribution to society is continuing to discover and develop innovative medicines that help make life better. Being a trustworthy global citizen also requires us to conduct our business ethically, responsibly and transparently."

Last month, the company announced plans to expand its worldwide insulin manufacturing capabilities, in order to help address the growing global demand for diabetes medication.